Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion

Journal of Nuclear Medicine

Volumn 48, Issue 2, 2007, Pages 269-276

  Mårtensson, Linda ^a,c   Nilsson, Rune ^b   Ohlsson, Tomas ^a   Sjögren, Hans Olov ^a   Strand, Sven Erik ^a   Tennvall, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

^b Mitra Medical AB   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibody; Oncology; Radioimmunotherapy; Radionuclide therapy; Syngeneic tumor model

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1033 BR96 LU 177; 1033 BR96 Y 90; ANTIBODY CONJUGATE; BIOTIN; BR96 LU 177; BR96 Y 90; INDIUM 111; MITRATAG; MONOCLONAL ANTIBODY; RADIOISOTOPE; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DIAGNOSTIC AGENT; IMMUNOTOXIN; INDIUM; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TUMOR LEVEL; EXTRACORPOREAL AFFINITY ADSORPTION TREATMENT; EXTRACORPOREAL CIRCULATION; IMMUNOCOMPETENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCINTILLATION CAMERA; TUMOR MODEL; ADSORPTION; ANIMAL; BLOOD; BONE MARROW DISEASE; BROWN NORWAY RAT; CANCER TRANSPLANTATION; IMMUNOLOGY; ISOGRAFT; METABOLISM; NEOPLASM; PATHOLOGY; RADIATION INJURY; SCINTISCANNING;

ADSORPTION; ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW DISEASES; EXTRACORPOREAL CIRCULATION; HETEROCYCLIC COMPOUNDS, 1-RING; IMMUNOCONJUGATES; IMMUNOTOXINS; INDIUM RADIOISOTOPES; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RATS; RATS, INBRED BN; TRANSPLANTATION, ISOGENEIC;

EID: 34047201766     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792-7798.
2. Waddick KG, Chae HP, Tuel-Ahlgren L, et al. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. Radiat Res. 1993;136:313-319.
3. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood. 2004;103:1485-1494.
4. Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ. The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma. Blood. 1999;94:233-243.
5. Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med. 2005;46(suppl):141S-150S.
6. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46:149-168.
7. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
8. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999;26:348-357.
9. Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal whole-blood immuno-adsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody. J Nucl Med. 1997;38:895-901.
10. Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents: reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem. 2002;13:1079-1092.
11. 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm. 2005;20:457-466.
12. y-related cell surface antigens. Cancer Res. 1990;50:2183-2190.
13. 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res. 2005;11(suppl):7104s-7108s.
14. Wang Z, Martensson L, Nilsson R, et al. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N′, N″,N‴-tetraacetic acid and biotin before radiolabeling. Clin Cancer Res. 2005;11(suppl): 7171s-7177s.
15. Green NM. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J. 1965;94:23c-24c.
16. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
17. Monti P, Wysocki J, van der Meeren A, Griffiths NM. The contribution of radiation-induced injury to the gastrointestinal tract in the development of multiorgan dysfunction syndrome or failure. BJR Suppl. 2005;27:89-94.
18. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80(suppl):2591-2610.
19. Stabin MG, Peterson TE, Holburn GE, Emmons MA. Voxel-based mouse and rat models for internal dose calculations. J Nucl Med. 2006;47:655-659.
20. Sharkey RM, Blumenthal RD, Goldenberg DM. Anti-antibody enhancement of tumor imaging. Cancer Treat Res. 1990;51:433-455.
21. Ullen A, Ahlstrom KR, Heitala S, Nilsson B, Arlestig L, Stigbrand T. Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Acta Oncol. 1996;35:281-285.
22. Sato N, Saga T, Sakahara H, et al. Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice. Jpn J Cancer Res. 2000;91:622-628.
23. Li GP, Wang YX, Huang K, Zhang H, Zhang CF. Avidin chase reduces side effects of radioimmunotherapy in nude mice bearing human colon carcinoma. World J Gastroenterol. 2005;11:1917-1921.
24. Blumenthal RD, Lew W, Reising A, et al. Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. Int J Cancer. 2000;86:276-280.
25. Alisauskas RM, Goldenberg DM, Sharkey RM, Blumenthal RD. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. Int J Cancer. 1997;70:323-329.
26. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res. 1995;55(suppl):5916s-5920s.